Clinical trial results with MPA/E2C.
Results of a multicenter, controlled U.S. trial that evaluated a new monthly combination injectable have confirmed that the injectable formulation is both highly effective and well tolerated. The results of the U.S. trial are consistent with clinical studies conducted in other countries by the WHO and suggest that this new contraceptive method will expand clinical options for preventing pregnancy. The specific advantages of the monthly injectable formulation include infrequent dosing, rapid reversibility and a degree of efficacy that rivals sterilization.
Shulman
L P
LP
Department of Obstetrics and Gynecology, University of Illinois at Chicago 60612-7313, USA. shulman@uic.edu
D017326:Clinical Trials, Phase III as Topic; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D014481:United States
D003271:Contraceptive Agents, Female; C403500:Lunelle; D004958:Estradiol; D017258:Medroxyprogesterone Acetate